TREM1 antibody

Catalog No. ABIN2191849

Product Details anti-TREM1 Antibody

Target: TREM1 (Triggering Receptor Expressed On Myeloid Cells 1 (TREM1))

Reactivity: Mouse

Host: Rat

Clonality: Monoclonal

Conjugate: This TREM1 antibody is un-conjugated

Application: Western Blotting (WB), Flow Cytometry (FACS), Immunofluorescence (IF), Functional Studies (Func)

Sterility: 0.2 μm filtered

Clone: L5-B8

Application Details

Application Notes: For immunohistology, flow cytometry and Western blotting, dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:50. For functional studies, in vitro dilutions have to be optimized in user's experimental setting.

Restrictions: For Research Use only

Handling

Buffer: PBS, containing 0.1 % bovine serum albumin.

Storage: 4 °C

Storage Comment: Product should be stored at 4 °C. Under recommended storage conditions, product is stable for one year.

Expiry Date: 12 months

Target Details for TREM1

Target: TREM1 (Triggering Receptor Expressed On Myeloid Cells 1 (TREM1))

Alternative Name: Triggering Receptor Expressed On Myeloid Cells 1 (TREM1 Products)

Synonyms: TREM1 antibody, CD354 antibody, TREM-1 antibody, triggering receptor expressed on myeloid cells 1 antibody, TREM1 antibody, Trem1 antibody, LOC100349504 antibody

Background: The monoclonal antibody L5-B8 recognizes mouse triggering receptor expressed on myeloid cells-1 (TREM-1). TREM-1 is a 30 kDa monomeric transmembrane activating receptor. TREM-1 is a member of the immunoglobulin superfamily. TREM-1 is expressed at low levels in the early development of the hematopoietic system in the promonoistic stage, and at high levels on the surface of immune cells, including neutrophils, monocytes and macrofages. TREM-1 is synthesized as a 234 amino acid (aa) precursor with a signal peptide (16 aa), an extracellular domain (184 aa), a transmembrane domain (29 aa), and a short cytoplasmic domain (5 aa). The short intracellular domain associates with a signal- transduction molecule, DNAX-activation protein 12 (DAP12), triggering the secretion of inflammatory cytokines that amplify the host response to microbial agents. TREM-1 acts in synergy with Toll-like receptor signaling pathways in amplifying the inflammatory response. Platelets express a natural ligand for TREM-1. The expression of TREM-1 is greatly upregulated on phagocytic cells in the presence of bacteria and fungi. TREM-1 has a role in sepsis, inflammatory bowel disease (IBD) and multiple sclerosis. In contrast, TREM-1 is not upregulated in samples from patients with non-inefctious inflammatory conditions. During infections, receptor expression is modulated and soluble TREM-1 (sTREM-1, 17 kDa) is released. TREM-1 is shed from the membrane of activated phagocytes and can be found as sTREM-1 in body fluids like plasma and bronchoalveolar lavage fluid (BAL). Elavated levels of sTREM-1 have a accuracy and sensitivity in detecting microbial infections as underlying disease. Furthermore, sTREM-1 has been associated with non-infectious inflammatory conditions like major abdominal surgery, peptic ulcer disease and COPD. Aliases TREM-1, triggering receptor expressed on myeloid cells, TREM1 Immunogen Mouse TREM-1-human IgG-Fc fusion protein